CIHR and its partners are pleased to announce a new direction and partnership for the initiative in Regenerative Medicine and Nanomedicine. The Canadian Space Agency (CSA) has joined in supporting New Discoveries: High-Risk Seed grants that meet the strategic goals of its Space Life Sciences Program.
The June 2004 Request for Applications (RFA) provides a mechanism for research support in the areas of Nanomedicine and Technology Development, Gene Therapy, Stem Cells, Tissue Engineering and Rehabilitation Sciences. This support is offered through innovative Team Grants and New Discoveries: High-Risk Seed Grants - a variation of the tools available in the initial 2003 launch. Additional specific partnered programs are also available, as described in the June 2004 RFA announcement.
As part of the revised June 2004 RFA, the Canadian Space Agency will consider funding New Discoveries grants in nanomedicine relating to diagnostics, bio-sensors and associated hardware for use in space. The CSA will also support high quality ground-based research leading to tissue engineering in microgravity through the New Discoveries granting program. To encourage innovative and diversified ideas, proposals in the area of tissue engineering in space will not otherwise be restricted to specific areas of research.
For full details on all funding programs available through the Regenerative Medicine and Nanomedicine initiative, please see the June 2004 RFA announcement.